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Preeclampsia is a pregnancy-speciﬁc syndrome, deﬁned by such clinical hallmarks as the
onset of maternal hypertension and proteinuria after 20 weeks of gestation.The syndrome
is also characterized by impaired blood ﬂow through the utero-placental circulation and
relative placental ischemia, which in turn, may generate feto-placental endothelial dysfunc-
tion. Endothelial dysfunction in offspring born from preeclamptic pregnancies has been
associated with an increased risk of cardiovascular disease, including hypertension, later in
life. Interestingly, diminished endothelial function, manifested by low angiogenic capacity,
leads to hypertension in animal studies. Recently, we have shown that the adenosine
receptor A2A/nitric oxide/vascular endothelial growth factor axis is reduced in human
umbilical vein endothelial cells derived from preeclamptic pregnancies, an effect correlated
with gestational age at onset of preeclampsia. We and others suggested that impaired
vascular function might be associated with high cardiovascular risk in offspring exposed
to pregnancy diseases. However, we are not aware of any studies that examine impaired
adenosine-mediated angiogenesis as a possible link to hypertension in offspring born from
preeclamptic pregnancies. In this review, we present evidence supporting the hypothesis
that reduced adenosine-mediated angiogenesis during preeclamptic pregnancies might be
associated with development of hypertension in the offspring.
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INTRODUCTION
Preeclampsia is a major cause of maternal and infant morbid-
ity and mortality worldwide (Xiong et al., 2002; Duley, 2009).
Stillbirth is more common in preeclamptic pregnancies, and one
third of infants of preeclamptic women exhibit growth restriction.
Furthermore, the appropriate management of preeclampsia (i.e.,
delivery of women with increasingly severe disease) is responsible
for 8% of preterm births, with attendant increased morbidity and
mortality (Sibai et al., 2005; Villar et al., 2006). In the last 30 years,
it has become evident that the fetal intrauterine environment has
long-lasting consequences for the infant. Low or high birth weight,
Abbreviations: NECA, 5′-N-ethylcarboxamido-adenosine; AP-1, Activator pro-
tein 1; AR, adenosine receptor; A2AAR, adenosine receptor A2A; A2BAR, adenosine
receptor A2B; bFGF, basic ﬁbroblast growth factor; EOPE, early-onset preeclampsia;
eNOS, endothelial nitric oxide synthase; EPC, endothelial progenitor cells; hENT1,
equilibrative nucleotide transporter type 1; hENT2, equilibrative nucleotide trans-
porter type 2; Epac, exchange protein activated by cAMP ; ERK, extracellular
signal-regulated kinase; hPMEC, human placental microvascular endothelial cell;
HUVEC, human umbilical vein endothelial cell; HIF-1α, hypoxia inducible factor
type 1 α; IL-8, interleukin 8; LOPE, late-onset preeclampsia; MAPK, mitogen-
activated protein kinase; LLC, mouse Lewis lung carcinoma; NO, nitric oxide; PKA,
protein kinase A; sFlt-1, soluble vascular endothelial growth factor receptor type
1 or soluble fms-like tyrosine kinase-1; sEnd, soluble endoglin; VEGF, vascular
endothelial growth factor.
prematurity, gestational diabetes, and hypertension not only have
an impact on perinatal outcomes; they also have long-term conse-
quences, increasing the risk of neurological disability, obesity, and
cardiovascular disease in adult life (Gluckman and Hanson, 2004;
Hanson and Gluckman, 2008; Krause et al., 2009). The multi-
organ dysfunction syndrome associated with preeclampsia could,
directly or indirectly, affect the intrauterine environment.
The underlying pathophysiology of preeclampsia includes dys-
regulation of endothelial function in both the maternal and the
feto-placental circulation (Roberts and Escudero, 2012). Several
groups have suggested that long-term complications in offspring
from preeclamptic pregnancies might be associated with loss
of the endothelium’s ability to regulate vascular tone by syn-
thesizing vasoactive molecules. However, the endothelium is
also responsible for the generation of new vessels through the
process of angiogenesis. Imbalance of angiogenic factors (i.e.,
reduction in the activity of pro-angiogenic factors in associa-
tion with high activity/expression of the anti-angiogenic factors)
is a well-characterized feature of preeclampsia. The implication
of this imbalance for the occurrence of long-term complica-
tions in offspring from preeclamptic pregnancies is not yet
clear. Since adequate formation of blood vessels is required
for controlling blood pressure and for tissue repair, it is likely
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that impaired angiogenesis may contribute to future cardio-
vascular risk in the newborn “exposed” to preeclampsia in
utero.
Adenosine is a naturally occurring nucleoside, which is
increased in the feto-placental circulation with preeclampsia
(Yoneyama et al., 1996; Escudero et al., 2009; Espinoza et al.,
2011). It plays an important role in controlling the production
and action of pro-angiogenic factors such as vascular endothelial
growth factor (VEGF), as well as anti-angiogenic factors includ-
ing soluble fms-like tyrosine kinase-1 (sFlt-1; George et al., 2010)
and, through this mechanism, may control placental angiogenesis
(Escudero et al., 2012). Therefore, it is plausible that dysfunctional
adenosine-mediated angiogenesis in utero and after birthmay con-
tribute to long-term complications in offspring from preeclamptic
pregnancies.
PATHOPHYSIOLOGY OF PREECLAMPSIA: CURRENT
HYPOTHESES
Preeclampsia has been deﬁned by the onset of hypertension and
proteinuria after 20 weeks of gestation and is additionally charac-
terized by maternal endothelial dysfunction (Roberts et al., 1989).
However, recently The American College of Obstetricians and
Gynecologists has stated that proteinuria is no longer absolutely
required for diagnosis of preeclampsia (ACOG, Task Force of
Hypertension in Pregnancy, 2013). Alternatively, diagnosis may be
establishedby the presence of hypertension associatedwith throm-
bocytopenia (platelet count less than 100.000/μL), impaired liver
functions (elevated blood concentrations of liver transaminases up
to twice the normal concentration), development of renal insufﬁ-
ciency (serum creatinine concentration greater than 1.1 mg/dL or
a doubling of the serum creatinine concentration in the absence
of other renal diseases), pulmonary edema, or new-onset cerebral
or visual disturbances.
Current thinking on the pathophysiology of preeclamp-
sia suggests that impaired invasion of trophoblastic cells into
the maternal vascular bed leads to aberrant transformation of
uterine resistance vessels to large diameter capacitance vessels
(Burton et al., 2009a,b). This reduces maternal blood ﬂow to
the placenta and generates relative ischemia. Failure to increase
the terminal caliber of the spiral arteries results in increased
velocity of blood entering the intervillus space, with conse-
quent shear stress on the fetal villus trophoblast (Burton et al.,
2009b), leading to cell damage, detachment, and the release
of cell fragments into the maternal circulation (Tannetta et al.,
2013). These fragments contain elements that may impair
maternal endothelial function and generate a vicious cycle that
will chronically affect maternal and feto-placental endothelial
function.
Amongmolecules released from theplacenta, sFlt-1 has become
a focus of study in preeclampsia. It is increased in the blood
of women prior to and during clinical preeclampsia and has
the potential to blunt angiogenic responses. Importantly, reduc-
tion of the plasma level of sFlt-1 in women with preterm
preeclampsia using dextran sulfate apheresis has been reported
to reduce proteinuria and blood pressure and prolong pregnancy
by 23 days without apparent adverse events for mother or fetus
(Thadhani et al., 2011). Moreover, the injection of mice with ade-
novirus expressing sFlt-1 results in pathophysiological ﬁndings
resembling preeclampsia (Maynard et al., 2003; Bytautiene et al.,
2011; Murphy et al., 2012). This animal model has been employed
to study not only the pathophysiology of preeclampsia but also
vascular alterations in the offspring (Lu et al., 2007a; Byers et al.,
2009; Bytautiene et al., 2011).
DEVELOPMENTAL ORIGINS OF ADULT DISEASE AFTER
PREECLAMPSIA
The fetal programming hypothesis proposes that chronic diseases
may originate through adaptations of the fetus to an adverse
intrauterine environment. These adaptationsmay include changes
in the vascular, metabolic, or endocrine systems. Those changes
permanently affect function in adult life.
Numerous epidemiological studies suggest an important role
for the adverse intrauterine environment in the development of
schizophrenia, depression, cardiovascular diseases, stroke, dia-
betes, cancer, pulmonary hypertension, osteoporosis, polycystic
ovarian syndrome, and other conditions in adult life. These
observational relationships are supported by animal experiments
in which effects on fetal growth via manipulation of maternal
nutrition or reduction of blood ﬂow to the placenta (by various
approaches) result in obesity, increased blood pressure, and other
cardiovascular abnormalities in the offspring later in life (Hanson
and Gluckman, 2008; Glover, 2011; Davis et al., 2012b). Applying
this concept to preeclampsia brings in a number of other insults
which may trigger programming. These include increased oxida-
tive stress and elevated concentration of anti-angiogenic factors,
which can also result in growth restriction or premature deliveries.
PREECLAMPSIA AND LONG-TERM ADVERSE OUTCOMES IN THE
OFFSPRING
Many epidemiological studies (Kajantie et al., 2009; Wu et al.,
2009, 2011; Davis et al., 2012a,b; Lawlor et al., 2012) indicate that
preeclampsia is associated with long-term adverse outcomes in
the offspring. The majority of studies (Palti and Rothschild, 1989;
Seidman et al., 1991; Tenhola et al., 2003, 2006; Vatten et al., 2003;
Swarup et al., 2005; Hiller et al., 2007; Oglaend et al., 2009; Kvehau-
gen et al., 2010; Lazdam et al., 2010; Palmsten et al., 2010; Lawlor
et al., 2012), but not all (Ounsted et al., 1983; Jayet et al., 2010;
Belfort et al., 2012; Lawlor et al., 2012) report that children and
adolescents who were exposed to preeclampsia or hypertension
in pregnancy exhibit higher systolic and diastolic blood pressure
compared with non-exposed children or adolescents. These stud-
ies were reviewed in a recent meta-analysis (Davis et al., 2012a),
which included individuals aged 4–30 years, born at term from
preeclamptic pregnancies. This meta-analysis concluded that off-
spring born from preeclamptic women had ∼2 mm Hg greater
systolic and ∼1.3 mm Hg greater diastolic blood pressure than
individuals born from normotensive pregnancies. Interestingly,
according to their prediction, “if the 2.4 mmHg difference in sys-
tolic blood pressure tracks into adulthood (Chen andWang, 2008),
this difference would be associated with an ∼8% increased risk of
mortality from ischemic heart disease and 12% increased risk from
stroke” (Davis et al., 2012a). Based on a study in a large population
of preeclamptic pregnancies, Kajantie et al. (2009) reported that
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the risk for stroke in subjects born from preeclamptic pregnancies
was twice that of controls born from normotensive pregnancies.
Other studies have described an increased risk for pulmonary
hypertension (Jayet et al., 2010), metabolic and endocrine dis-
ease (Wu et al., 2009, 2011), depression (Tuovinen et al., 2010),
cerebral palsy (Szymonowicz and Yu, 1987), poor cognitive out-
come (Cheng et al., 2004), or intellectual disabilities (Grifﬁth et al.,
2011) in children born of preeclamptic pregnancies compared to
non-exposed children.
These clinical and epidemiological observations are supported
by a recent review of animal models of preeclampsia (Davis
et al., 2012b), including those generated by systemic hypoxia, by
mechanical reduction of maternal uterine artery blood ﬂow, in
genetically modiﬁed animals lacking endothelial nitric oxide syn-
thase (eNOS), or by overexpression of sFlt-1 by infection with
adenovirus carrying this protein. Notwithstanding differences in
design and outcome of these models, the conclusion was that
“animal studies support the potential relevance of these insults
to programming of offspring blood pressure.”
Although fetal programming by preeclampsia is suggested by
human and animal studies, it is not easy to determine whether
preeclampsia per se leads to high cardiovascular risk in the off-
spring or whether related factors, such as intrauterine growth
restriction or preterm delivery, contribute. To allay these concerns,
most studies have excluded individuals exposed to preterm deliv-
ery or intrauterine growth restriction associated with preeclamp-
sia. Interestingly, the risks for hypertension, impaired neurological
function, and stroke in offspring from preeclamptic pregnancies
remain signiﬁcant (Kajantie et al., 2009; Tuovinen et al., 2010,
2012). Moreover, a study performed in brothers exposed, or
not, to preeclampsia suggested that impaired vessel function was
associated with preeclampsia per se rather than genetic predispo-
sition (Jayet et al., 2010). It is plausible, then, that exposure to
preeclampsia in utero can predispose to adverse outcomes later in
life.
Understanding the underlying mechanisms might suggest
interventions to prevent the occurrence of future chronic dis-
ease in offspring exposed to preeclampsia. Several groups (Jayet
et al., 2010; Lazdam et al., 2010; Kvehaugen et al., 2011; Davis
et al., 2012a,b; Lawlor et al., 2012), including ours (Escudero
and Sobrevia, 2008; Escudero et al., 2012), have presented evi-
dence of endothelial dysfunction in the feto-placental circula-
tion in preeclampsia, which may be a precursor to the long-
term complications observed in offspring born of preeclamptic
pregnancies.
ENDOTHELIAL DYSFUNCTION AND IMPAIRED
ANGIOGENESIS IN OFFSPRING BORN FROM PREECLAMPTIC
PREGNANCIES
Endothelial dysfunction is a pathological state characterized by
an imbalance between vasodilators and vasoconstrictors pro-
duced by (or acting on) the endothelium (Brunner et al., 2005).
Infants born of preeclamptic pregnancies have evidence of
endothelial dysfunction shortly after delivery and months to
years later (Davis et al., 2012a,b; Sobrevia et al., 2012; Wadsack
et al., 2012). For instance, reduced ﬂow-mediated vasodilata-
tion (a hallmark of endothelial dysfunction) has been reported
in children born from preeclamptic pregnancies as compared
to children born from normotensive pregnancies (Jayet et al.,
2010; Lazdam et al., 2010; Kvehaugen et al., 2011; Davis et al.,
2012b). In animal studies using mice, male offspring born
from mothers with preeclamptic-like syndrome, generated by
administration of adenovirus carrying sFlt-1, exhibited high
blood pressure (Lu et al., 2007a,b) and increased vascular reac-
tivity (Byers et al., 2009; Bytautiene et al., 2011) compared to
controls.
It is also clear that endothelial cells are main contributors to
angiogenesis (Shibuya, 2006; Escudero et al., 2009), which leads
to the growth of new blood vessels from pre-existing ones. The
endothelium participates in angiogenesis through several pro-
cesses, which include cell proliferation/migration, tube formation,
as well as synthesis and release of pro-angiogenic factors including
VEGF (Shibuya, 2013). In addition, neovasculogenesis, a process
of blood vessel formation occurring by de novo production of
endothelial cells, can occur not only at the embryonic stage but
also in adult life (Risau, 1997). Endothelial progenitor cells (EPCs)
play a critical role in postnatal blood vessel formation and vascular
homeostasis. In preeclampsia, impaired feto-placental angiogene-
sis (Escudero et al., 2009, 2012, 2014) and neovasculogenesis (due
to the reduced number of EPCs found in umbilical cord blood
(Kwon et al., 2007; Xia et al., 2007; Monga et al., 2012) may be a
result of endothelial dysfunction.
Reduced placental levels of several pro-angiogenic factors have
been reported in the feto-placental circulation in early-onset
preeclampsia (EOPE) when these are compared to late-onset
preeclampsia (LOPE) or to age-matched controls (Gellhaus et al.,
2006; Junus et al., 2012). Microarray analysis reveals lower expres-
sion of at least two angiogenesis-associated transcripts (Egﬂ7 and
Acvrl1) in EOPE compared to LOPE or age-matched controls
(Junus et al., 2012). Recently, we have reported that the pro-
liferation/migration of human umbilical vein endothelial cells
(HUVEC) is reduced in EOPE compared to LOPE or controls,
whereas cells from LOPE exhibit elevated proliferation/migration
compared to controls (Escudero et al., 2012). These reports sug-
gest that angiogenesis could be modiﬁed in the feto-placental
circulation in preeclampsia.
The mechanisms underlying impaired neovascularization in
feto-placental circulation during preeclampsia are under investi-
gation and may be associated with the reduced numbers of EPCs
observed in umbilical blood (Kwon et al., 2007; Xia et al., 2007;
Monga et al., 2012), an increase in circulating anti-angiogenic
factors such as sFlt-1 (Staff et al., 2005; Tsao et al., 2005) and
soluble endoglin (sEnd; Staff et al., 2007), or reduced expres-
sion and activity of pro-angiogenic signals such as VEGF (Lyall
et al., 1997; Andraweera et al., 2012; Kim et al., 2012) or adeno-
sine (Escudero et al., 2012). As presented in Figure 1, this
imbalance is manifested mainly by elevation of sFlt-1and sEnd,
associated with reduced numbers of EPCs, which may nullify
pro-angiogenic signals from VEGF and placental growth factor
(PlGF).
Several prior studies have examined feto-placental tissue; how-
ever, few studies (see for instance Staff et al., 2005; Tsao et al.,
2005; Kvehaugen et al., 2010, 2011) have assessed endothelial dys-
function postnatally in newborn infants or children exposed to
www.frontiersin.org June 2014 | Volume 5 | Article 134 | 3
Escudero et al. Adenosine and programming during preeclampsia
FIGURE 1 | Imbalance of pro- and anti-angiogenesis in feto-placental
circulation during preeclampsia. Represented is the reduction in
expression and/or action of pro-angiogenic factors such as vascular
endothelial growth factor (VEGF), placental growth factor (PlGF),
adenosine, nitric oxide (NO), angiopoietin 1 (Ang1) and 2 (Ang2), and
angiopoietin tyrosine kinase (Tie2), as well as reduction in the number of
endothelial progenitor cells (EPC) exhibited in umbilical blood derived from
preeclamptic pregnancies. On the other hand, elevated levels of
anti-angiogenic factors such as soluble receptor type 1 of VEGF (sFlt-1) and
soluble endoglin receptor (sEnd) have been also reported in umbilical
circulation from preeclampsia.
preeclampsia. Considering that placental blood vessels on the fetal
side form a continuous network with fetal systemic circulation,
it is pertinent to ask whether offspring exposed to preeclampsia
exhibit endothelial dysfunction and impaired angiogenesis after
birth.
To the best of our knowledge, there is no direct answer to this
question. However, indirect evidence includes increased concen-
trations of sFlt-1 in the fetus from preeclamptic pregnancies as
measured in umbilical cord blood (Staff et al., 2005; Tsao et al.,
2005). Offspring with high blood pressure whose parents also had
high blood pressure showed fewer capillaries in the dorsum of
the ﬁnger compared with either offspring with low blood pres-
sure whose parents were either normotensive or hypertensive or
hypertensive offspring whose parents were normotensive (Noon
et al., 1997). More recently, Yu et al. (2012) reported that children
born from preeclamptic pregnancies exhibited a 45% reduction in
the risk of retinopathy of prematurity, a well-described example
of pathological angiogenesis in premature infants, compared to
preterm babies born from normotensive pregnancies. Moreover,
Stark et al. (2009), studying blood ﬂow immediately after birth
in the microcirculation of children born from preeclamptic preg-
nancies, found altered fetal microvascular structure and function,
particularly in male newborns.
In animal studies, at postnatal day 7, rat pups from spon-
taneously hypertensive mothers, exposed to hypoxic-ischemic
brain injury, exhibited less brain damage than pups from nor-
motensive mothers (Letourneur et al., 2012). Interestingly, this
apparently protective phenomenon was associated with deﬁcits in
motor coordination and spatial learning in pups from hyperten-
sive, compared to normotensive mothers. These results could be
interpreted as a consequence of impaired angiogenesis. This could
reduce the area of the lesion but also impair tissue recovery after
ischemic insult in the brain. Therefore, it is plausible that off-
spring born from preeclamptic pregnancies may exhibit reduced
angiogenic processes after birth, which may lead to cardiovascular
complications later in life.
The latter concept is supported by the following ﬁndings: (1)
VEGFR2 gene expression decreases with development (Greene
et al., 2011). Also, vessel branching in the brain increases until
10 days postpartum and stabilizes to adult levels between days 10
and 25 in mice (Harb et al., 2013); (2) mature (4–5 month old)
mouse brains lose their ability to undergo angiogenesis in response
to hypoxia (Harb et al., 2013), suggesting that the process of angio-
genesis, even in stressful conditions, is limited after birth; (3)VEGF
production and activity are both impaired in the feto-placental
circulation during preeclampsia (Lyall et al., 1997; Andraweera
et al., 2012; Kim et al., 2012); (4) Inhibition of angiogenesis with
humanized antibodies targeting VEGF or orally active small tyro-
sine kinase inhibitors targeting VEGF receptors is commonly
associated with severe hypertension (Lankhorst et al., 2013); (5)
Loss of microvessel growth has been reported to precede eleva-
tions in blood pressure (Murfee and Schmid-Schonbein, 2008);
(6) Programming of elevated blood pressure in the offspring
has been associated with a reduced angiogenic capacity of ves-
sels cultured in vitro (Pladys et al., 2005). Taking all these data
into account, we believe that abnormal angiogenic processes
present after birth in offspring born from preeclamptic preg-
nancies may contribute to elevation in blood pressure later in
life.
OVERVIEW OF ADENOSINE RECEPTORS
ADENOSINE RECEPTORS AND ANGIOGENESIS
Adenosine is a purinergic nucleoside which controls several phys-
iological processes, including angiogenesis and vasculogenesis.
Adenosine activates a family of G-coupled adenosine receptors,
A1AR, A2AAR, A2BAR, and A3AR (Olah and Stiles, 2000; Jacobson
and Gao, 2006). All of the adenosine receptors have been impli-
cated in the modulation of angiogenesis (see Table 1). Brieﬂy,
stimulation of A1AR on embryonic EPCs promotes their adher-
ence to the vascular endothelium, suggesting an important role
for this receptor subtype in vasculogenesis (Ryzhov et al., 2008).
A1AR have also been reported to upregulate VEGF production
from monocytes, thus promoting angiogenesis (Clark et al., 2007).
Depending on the tissue or cell studied, A2AAR and A2BAR
can play a dominant role in the regulation of angiogenic
factors. For example, A2BAR upregulates the pro-angiogenic
factors VEGF, basic ﬁbroblast growth factor (bFGF), insulin-
like factor-1, and interleukin 8 (IL-8) in human microvascular
endothelial cells (Grant et al., 1999; Feoktistov et al., 2002). Con-
versely, A2AAR is reported to upregulate VEGF in macrophages
(Leibovich et al., 2002; Pinhal-Enﬁeld et al., 2003). Stimulation of
A3AR in mast cells and some tumors can result in upregulation
of pro-angiogenic factors, complementing the actions of adeno-
sine mediated via A2BAR (Feoktistov et al., 2003). Of interest,
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stimulation of A2AAR in HMEC-1 inhibits the release of the anti-
angiogenic factor thrombospondin 1, providing yet anothermeans
by which adenosine may regulate angiogenesis (Desai et al., 2005;
see Table 1).
While A2AAR and A2BAR have been shown to mediate the
proliferative actions of adenosine in human retinal microvascu-
lar endothelial cells (Grant et al., 1999, 2001), HUVEC (Feoktistov
et al., 2004; Escudero et al., 2012), or porcine coronary artery and
rat aortic endothelial cells (Dubey et al., 2002), it remains unclear
whether A1AR andA3AR are functionally expressed and what role,
if any, they play in endothelial cells (Wyatt et al., 2002; Schaddelee
et al., 2003).
ADENOSINE RECEPTORS AND INTRACELLULAR PATHWAYS DURING
ANGIOGENESIS
Although some data suggest that cAMP may play a role in the
pro-angiogenic effects of adenosine in certain cells (Takagi et al.,
1996), other studies show that upregulation of angiogenic factors
is mediated via coupling to Gq, possibly involving mitogen-
activated protein kinase (MAPK) pathways (Grant et al., 1999,
2001; Feoktistov et al., 2002; Ryzhov et al., 2014). Further studies,
using HMEC-1 demonstrated that adenosine receptor-dependent
upregulation of VEGF production was associated with an increase
in VEGF transcription, activator protein 1 (AP-1) activity and
transcription factor JunB (JunB) accumulation (Ryzhov et al.,
2014).
Mechanistically, A2BAR which are coupled to both Gs and
Gq proteins (Feoktistov and Biaggioni, 1995) increase JunB
protein levels and VEGF production via stimulation of pro-
tein lipase C and extracellular signal-regulated kinase (ERK),
which are possibly linked by the calcium diacylglycerol gua-
nine nucleotide exchange factor (CalDAG-GEF)–Ras-proximate-1
(Rap1) pathway (Ryzhov et al., 2014). These effects were pro-
tein kinase A (PKA)-independent because the PKA inhibitors
had no effect on the A2BAR-dependent increase in JunB pro-
tein levels and VEGF production. Because VEGF secretion
and reporter promoter activity induced by the adenosine ana-
log 5′-N-ethylcarboxamido-adenosine (NECA) were inhibited
by the expression of a dominant, negative JunB or by JunB
knockdown, these data suggest an important role for the A2B
Table 1 | Summary of participation of adenosine receptor in angiogenesis using human cells.
AR K d (nM) Angiogenic process Cell type Reference
A1 3–30 Migration EPC Ryzhov et al. (2008)
A2A 1–20 VEGF expression
Thrombospondin 1 expression
sFlt-1 release
mFlt-1 expression
Proliferation/migration and VEGF expression
Macrophages
HMVEC
Macrophages
Macrophages
HUVEC
Pinhal-Enﬁeld et al. (2003), Ernens et al. (2010)
Desai et al. (2005)
Leonard et al. (2011)
Leonard et al. (2011)
Escudero et al. (2012)
A2B 5.000–20.000 Permeability
VEGF expression
Migration
VEGF, IL-8 and bFGF expression
Migration
VEGF and IL-8 expression
IL-8 secretion
VEGF expression
VEGF and IL-8 expression
Proliferation/migration and tube formation
and VEGF expression
HUVEC-PMN
HMVEC
HREC
HMEC-1
EPC
Foam cell
Melanoma cells, HT29
HUVEC under hypoxia
HMEC-1
HREC
Lennon et al. (1998)
Ryzhov et al. (2014)
Afzal et al. (2003)
Feoktistov et al. (2002)
Rolland-Turner et al. (2013)
Gessi et al. (2010)
Merighi et al. (2007, 2009)
Feoktistov et al. (2004)
Feoktistov et al. (2003)
Grant et al. (1999, 2001)
A3 > 1.000 Migration and tube formation
VEGF and IL-8 expression
VEGF and IL-8 expression
VEGF expression
Angiopoietin-2 expression
HUVEC
Foam cell
Melanoma cells
HT29
HMEC-1
Kim et al. (2013)
Gessi et al. (2010)
Merighi et al. (2009)
Merighi et al. (2007)
Feoktistov et al. (2003)
Kd (nM) for adenosine. VEGF, vascular endothelial growth factor; sFlt-1, soluble; mFlt-1, membrane-linked receptor type 1 for VEGF; IL-8, Interleukin 8; bFGF, basic
ﬁbroblast growth factor; HMVEC, human microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; PMN, polymorphonuclear leukocyte; HREC,
human retinal endothelial cells; HMEC-1, human microvascular endothelial cell line 1; EPC, endothelial progenitor cells; HT-29, human colon adenocarcinoma. Increase
( ) and decrease ( ) of pro or anti-angiogenic processes; AR, adenosine receptor.
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receptor-dependent upregulation of JunB in VEGF production
in various cell types, including endothelial cells (Ryzhov et al.,
2014).
Another study, in HUVEC, reported that adenosine-mediated
activation of ERK may involve an exchange protein activated
by cAMP (Epac), a component of a family of cAMP-activated
guanine nucleotide exchange factors for Rap GTPases (Fang
and Olah, 2007). Thus, A2BAR, coupled to Gαs promotes
activation of adenylyl cyclase and an increase in intracellu-
lar cAMP. In turn, cAMP activates Epac 1, which may then
activate a cascade of RapGTPase, B-Raf, and ﬁnally, ERK
(Fang and Olah, 2007), demonstrating an alternative pathway
for ERK activation involved in upregulation of pro-angiogenic
proteins.
In addition to JunB, the mediators downstream of ERK and
p38 MAPK activation may include molecules such as hypoxia
inducible factor type 1 α (HIF-1α) and/or nitric oxide (NO).
Using foam cells generated in vitro, Gessi et al. (2010) found
that activation of A3AR, A2BAR, and to a lesser extent, the
A2A subtypes were associated with the production of VEGF
induced by adenosine and hypoxia. This last effect was dependent
on activation of ERK, p38 MAPK, Akt, and HIF-1α. Further-
more, adenosine has been reported to increase the synthesis
of the angiogenic modulator NO in some, but not all, cul-
tured endothelial cells (Sobrevia et al., 1996; Li et al., 1998; Wyatt
et al., 2002). Whether, adenosine receptor-mediated activation
of ERK-MAPK-HIF-1α increases NO is unknown. But, it has
been reported that NO promotes a regulatory loop with ERK
activation/deactivation (Schieke et al., 1999) and stabilization of
HIF-1α and promotes HIF-1α binding to DNA (Kimura et al.,
2000).
EXPRESSION OF ADENOSINE RECEPTORS IN ENDOTHELIAL CELLS
DURING HYPOXIA
The expression of adenosine receptor subtypes and their func-
tion are subject to dynamic regulation by hypoxia (Bshesh et al.,
2002; Eltzschig et al., 2003; Feoktistov et al., 2004). Because the
A2BAR promoter contains a functional binding site for HIF-
1α (Kong et al., 2006), the onset of hypoxia strongly induces
A2BAR expression in different cell types including human der-
mal microvascular endothelial cells (Eltzschig et al., 2003), and
HUVEC (Feoktistov et al., 2004). In addition, elevated expres-
sion of A2AAR has also been reported after exposure to hypoxia
in human placental homogenate (Von Versen-Hoynck et al.,
2009), fetal chromafﬁn-derived cell line (Brown et al., 2011),
and human lung endothelial cells, while no evidence of A2AAR
upregulation was seen in mouse endothelial cells (Ahmad et al.,
2009).
Interestingly, despite the fact that all adenosine recep-
tors contain a hypoxia response element in their promoters
(St. Hilaire et al., 2009), regulation via HIF is differentially mod-
ulated. Whereas A2BAR is regulated by HIF-1α, A2AAR is
regulated by HIF-2α, suggesting that transcriptional regulation
might be part of the switch of A2AAR toward A2BAR expres-
sion observed in HUVEC exposed to hypoxia (Feoktistov et al.,
2004). This switch may have important functional implica-
tions for regulation of angiogenesis. For example, in HUVEC,
adenosine does not stimulate VEGF secretion under normoxic
conditions, but hypoxia increases the expression of A2BAR,
which are then able to stimulate VEGF release (Feoktistov et al.,
2004). Therefore, we could speculate that switching the expres-
sion of adenosine receptor toward A2BAR rather than A2AAR
during hypoxia in the endothelium may offer some advantages
in the angiogenic process, since high levels of adenosine may
downregulate activation and/or expression of A2AAR as mech-
anisms of desensitization. But at the same time, upregulation
of A2BAR will enhance or maintain the pro-angiogenic capac-
ity of adenosine in conditions were high levels of this autocoid
are expected. It is likely that this phenomenon may occur in
preeclampsia.
ADENOSINE, ANGIOGENESIS, AND PREECLAMPSIA
ADENOSINE LEVELS DURING PREECLAMPSIA
The plasma level of adenosine is ﬁnely regulated by a series of
enzymes responsible for synthesis and catabolism (see details in
Escudero and Sobrevia, 2009). Compared with non-pregnant
women, normal, pregnant women exhibit increased synthesis,
but reduced catabolism, of adenosine (Yoneyama et al., 2000; Lee
et al., 2007). Several studies have described high adenosine lev-
els in both maternal (Yoneyama et al., 2001, 2002a,b,c) and fetal
blood (Yoneyama et al., 1996; Espinoza et al., 2011; Escudero
and Sobrevia, 2012) during preeclampsia, particularly in severe
preeclampsia, compared with normal pregnancies (Yoneyama
et al., 1996; Espinoza et al., 2011; Escudero and Sobrevia, 2012).
Unexpectedly, these high levels are associated with high adenosine
catabolism via adenosine deaminase 2 (ADA2; Yoneyama et al.,
2002a; Kafkasli et al., 2006) as well as elevated adenosine uptake
(Escudero et al., 2008). The causes and consequences of a high
extracellular adenosine level in both maternal and fetal circulation
during preeclampsia are unclear; however, it may be explained
by an adaptive mechanism (Casanello et al., 2007; Escudero and
Sobrevia, 2008, 2009, 2012; Escudero et al., 2009) associated with
vasodilation or angiogenesis in preeclamptic placenta as occurs
in other tissues, such as heart, muscle, or brain, in unfavor-
able conditions such as hypoxia (Eckle et al., 2007; Lofﬂer et al.,
2007).
The levels of adenosine in umbilical vein blood in preeclamp-
sia (1.7 vs. 0.5 μmol/L, preeclampsia vs. normal pregnancy;
Yoneyama et al., 1996; Espinoza et al., 2011) and in the cul-
ture medium of human placental microvascular endothelial cells
(hPMEC) from preeclamptic pregnancies (2.7 vs. 0.6 μmol/L) are
at least three times higher than in normal pregnancy (Escudero
et al., 2008), making it likely that, in preeclampsia, all adenosine
receptors are likely to be stimulated (Jacobson and Gao, 2006).
However, only a few reports havedescribed the effect of preeclamp-
sia on the expression and function of adenosine receptors
(Escudero et al., 2008, 2012; Kim et al., 2008; Von Versen-
Hoynck et al., 2009). Thus, reduced expression of A2AAR, with-
out changes in A2BAR (Escudero et al., 2008), was found in
hPMEC isolated from preeclamptic placentas, whereas reduced
A2AAR (Escudero et al., 2012) but higher A2BAR (Acurio et al.,
2014) expression levels were found in HUVEC from preeclamp-
sia. Yet, increased levels of all adenosine receptors have been
reported in placental homogenate from preeclamptic placentas
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compared with normal pregnancy (Von Versen-Hoynck et al.,
2009).
ADENOSINE RECEPTOR ACTIVATION IN PREECLAMPSIA
It has been shown that activation of A2AAR leads to reduction
in adenosine uptake by the equilibrative nucleotide transporter
type 1 (hENT1) and hENT2, whereas A2BAR activation increases
hENT2-mediated adenosine transport in cells from preeclamptic
placentas (Escudero et al., 2008). Therefore, during preeclampsia,
activation of adenosine receptors may control adenosine trans-
port and, hence, extracellular adenosine levels. However, because
adenosine levels are increased despite the elevation of total adeno-
sine uptake, it is expected that the production of adenosine from
sources such ATP or cell debris is higher in preeclampsia than in
normal pregnancy (Spaans et al., 2014).
Recently, we observed reduced protein abundance of A2AAR
in HUVEC derived from EOPE, but non-signiﬁcant changes in
LOPE, compared with cells from normal pregnancy. These ﬁnd-
ings were associated with a basal (i.e., without any treatment)
reduction in cell migration/proliferation of HUVEC in EOPE
comparedwith normal pregnancy or LOPE (Escudero et al., 2012).
In addition, CGS-21680 (an A2AAR agonist) and NECA sig-
niﬁcantly increased HUVEC migration/proliferation in normal
pregnancy, LOPE, and EOPE.However, considering that cells from
EOPE exhibited the lowest migration/proliferation in the basal
conditions, the magnitude of response to both adenosine recep-
tor agonists in migration and proliferation tends to be higher in
cells from EOPE than those from others groups. In agreement
with these results, VEGF expression was signiﬁcantly lower in
HUVEC from EOPE, but higher in LOPE, compared to normal
pregnancy. Also, CGS-21680 increases the protein abundance of
VEGF in normal and EOPE-derived cells, an effect blocked by
the A2AAR antagonist ZM-241385. Nevertheless, CGS-21680 did
not affect VEGF expression in HUVEC from LOPE, but ZM-
241385 led to a reduction (41 ± 6%, p < 0.05) in the level of
this protein compared to corresponding levels at basal condition,
suggesting that A2AAR is activated at basal condition in LOPE.
Thus, A2AAR-mediated HUVEC proliferation and migration was
associated with VEGF synthesis in normal pregnancy, LOPE, and
EOPE.
To elucidate potential intracellular pathways related to A2AAR
activation, we determined that CGS-21680 increased the synthesis
of NO as evidenced by activation of eNOS (i.e., the p-eNOS/eNOS
ratio) and nitrite and nitrotyrosine levels in HUVEC from nor-
mal pregnancies and EOPE, but not in LOPE. The stimulatory
effect observed in normal and EOPE cells was blocked by ZM-
241385 co-incubation. In contrast, ZM-241385 reduced NO
synthesis in LOPE cells compared to non-treated controls. Fur-
thermore, using the non-selective nitric oxide synthase inhibitor,
L-NAME, we found a signiﬁcant reduction in the HUVEC migra-
tion/proliferation responses and VEGF protein levels in cells from
normal pregnancies and LOPE, but not in EOPE cells stimulated
with CGS-21680.
Thus, our study demonstrated that activation of A2AAR is
associated with the following cascade: eNOS activation (i.e.,
ser1177 phosphorylation), NO synthesis, nitrotyrosine forma-
tion,VEGF expression, and cell proliferation/migration in normal
pregnancy. However, cells derived from EOPE and LOPE were
different in several aspects. Whereas EOPE cells exhibited low
A2AAR expression and reduction of NO/VEGF synthesis and
cell proliferation/migration; LOPE cells demonstrated increased
cell proliferation/migration, mediated in part through the same
pathway (seeFigure 2). Existence of this pathwaywas recently con-
ﬁrmed using selective shRNA for A2AAR in HUVEC. Knockdown
of A2AAR was associated with reduced formation of intracellular
cAMP, NO metabolites, VEGF protein level, and the capacity for
tube formation compared with controls (unpublished results).
As stated before, adenosine-dependent angiogenesis can be reg-
ulated by all four adenosine receptors. There is little information
on the role of A2BAR in the angiogenic process during preeclamp-
sia, whereas the participation of A1AR and A3AR in this process
is unknown. In primary cultures of hPMEC, a cell type with high
pro-angiogenic capacity compared to HUVEC (Dye et al., 2004),
we found that A2BAR may be constitutively activated in cells from
preeclamptic placentas, since the use of A2A/A2BAR inhibitors in
non-stimulated cells decreases adenosine uptake (Escudero et al.,
2008). More recently, we found that activation of A2BAR in
HUVEC accounts for at least 30%of the pro-proliferative response
mediated by adenosine or NECA (Acurio et al., 2014). These data
agree with prior reports (Feoktistov et al., 2002, 2004) that expo-
sure of HUVEC to hypoxia increases the expression of A2BAR,
which is then able to stimulate VEGF release.
HYPOTHESIS FOR A ROLE FOR ADENOSINE IN PREECLAMPSIA
In view of available information, we can speculate that during
preeclampsia, a condition associated with reduction in the expres-
sion and activity of A2AAR, a compensatory increase in the expres-
sion and/or activity of A2BAR occurs that tends to compensate
the impaired adenosine-mediated pro-angiogenic process. More-
over, since adenosine is pro-angiogenic, the reduction in A2AAR
expression and down activation of A2AAR-dependent intracellu-
lar pathway might be part of the apparent “adenosine paradox,”
in which increased adenosine levels do not stimulate angiogenesis
in preeclampsia. The mechanism underlying this phenomenon is
unclear, but may be associated with the capacity of adenosine to
regulate the expression of its receptors, as exhibited in cells such as
cardiomyocytes (Headrick et al., 2013) or PC12 cells (Saitoh et al.,
1994). In particular, PC12 exposure to A2AAR agonists reduces
ADORA2 gene expression (Saitoh et al., 1994), suggesting a tran-
scriptional regulation of A2AAR by adenosine. Whether similar
regulation is present in endothelium is unknown, but this is a pos-
sible mechanism for the pathophysiological deregulation observed
in preeclampsia.
Although the intracellular signaling pathway related to adeno-
sine receptor activation is an area of active research, only our
recent study suggested a potential adenosine receptor-dependent
mechanism in preeclampsia. On the basis of this study, we pro-
pose a model (Figure 2), in which low expression of A2AAR in
EOPE leads to reduction in NO and VEGF expression (Escudero
et al., 2012). The implication of these alterations for feto-placental
angiogenesis is poorly understood, but might involve changes in
the activation of HIF (Kimura et al., 2002) and changes in the
promoter activity of several proteins, including anti-angiogenic
factors such as thrombospondin 2 (MacLauchlan et al., 2011) or
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FIGURE 2 | Model of the effect of the A2AAR/NO/VEGF signaling
pathway in cell migration and proliferation during preeclampsia.
Late-onset preeclampsia (A) is associated with elevated activation of
A2A adenosine receptor, characterized by high (↑) eNOS activation, NO
formation, and nitrotyrosine formation (Y-nitration), associated with
enhancement of cell proliferation and migration. On the other hand,
early-onset preeclampsia (B) is associated with a reduction (↓) in the
abundance of A2A adenosine receptor, which in turn could be reduced
with a decline in eNOS activation, NO formation, and Y-nitration and
might explain the reduced HUVEC migration and proliferation observed
in this disease. Despite this hypothesis, it is unclear (?) whether NO
generated by A2A stimulation can modulate the expression or activation
of VEGF or activate other signaling pathways involved in cell migration
and proliferation in early-onset preeclampsia.
pro-angiogenic factors like VEGF (Kimura et al., 2002; Feoktistov
et al., 2004). Considering that NO can cause nitration of tyrosine
residues on HIF-1α (Riano et al., 2011), and may contribute to sta-
bilization, we propose that the reduced adenosine-mediated NO
synthesis observed in EOPE might be associated with impaired
HIF-dependent VEGF expression (see Figure 3). Clearly, more
studies are necessary to understand all the processes involved in
these alterations.
Another question that needs to be answered is whether
impaired adenosine-mediated angiogenesis in the feto-placental
circulation of preeclamptic pregnancies persists after birth. In this
context, Coney and Marshall (2010) have demonstrated that pre-
natal hypoxia has long-lasting effects on vascular function in the
skeletal muscle of adult male rats. In particular, in a group of adult
males, they investigated how chronic systemic hypoxia in utero
(CHU) affects the cardiovascular response evoked by acute, sys-
temic hypoxia. One of the most intriguing results was the fact that
the overall magnitude of vasodilator response evoked in muscle
by acute systemic hypoxia is similar in CHU and normoxic rats,
but the mechanisms underlying the response appear to be differ-
ent. Thus, they conclude that, whereas in normoxia, vasodilatory
response is associated with the activation of endothelial A1AR
and NO-dependent effects, in CHU, participation of A1AR is
limited, and vasodilatory response in the muscle is replaced by
factors other than adenosine. Moreover, it has been reported
that mice deﬁcient in A2AAR (KO-A2AAR) exhibit no signiﬁ-
cant difference in systemic blood pressure compared to wild-type
animals, but they do develop pulmonary artery hypertension and
pulmonary vascular remodeling (Xu et al., 2011). Thus, these
studies demonstrate how the adenosine-impaired angiogenesis
and vascular remodeling observed in pathological pregnancies
such as preeclampsia may be related to future cardiovascular
risk.
CONCLUDING REMARKS AND FUTURE DIRECTIONS
That fetuses exposed to preeclampsia are at increased risk to
develop hypertension later in life has been associated with the
occurrence of endothelial dysfunction. Since the endothelium
is one of the main factors in the normal process of angiogen-
esis, an impaired endothelial/angiogenic response in offspring
from preeclamptic pregnancies may constitute the underlying
mechanism associated with hypertension. On the other hand,
preeclampsia is associated with elevated levels of adenosine and
low expression and response of A2AAR, but high expression of
A2BAR, defects that might be involved in abnormal placental and
newborn angiogenic processes. Then, adenosine may constitute
a potential new target for improving placental angiogenesis. Fur-
thermore, impairment of those mechanisms may contribute to
susceptibility to cardiovascular diseases, including hypertension,
in children exposed to preeclampsia.
As presented in this review, there are many questions that
need to be answered regarding adenosine-mediated angiogene-
sis in preeclampsia. Therefore, future studies should consider at
least the following inquires. Why A2AAR expression is reduced in
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FIGURE 3 | Reduced A2AAR/NO signaling pathway may involve
HIF nitration. It has been hypothesized that nitration of hypoxia
inducible factor (HIF) may control the expression of several genes,
including vascular endothelial growth factor (VEGF). Since adenosine
requires HIF for the induction of VEGF-promoter activity and because
this receptor triggers an intracellular signaling involving protein nitration
in normal and preeclamptic endothelial cells, it is unknown (?)
whether HIF-nitration after A2AAR stimulation might control HIF-binding
to a speciﬁc site (including –975 to –968; and –962 to –956) in the
VEGF promoter.
preeclampsia? Future studies should consider analysis of trans-
lational and transcriptional regulation of A2AAR expression in
endothelial cells derived from preeclampsia. Also, it should be
determined whether the reduction in total A2AAR levels observed
in preeclampsia, leads to a reduction in the cell surface expression
and in the activation of this receptor. Studies are also needed to
investigate how cross-talk between intracellular pathways related
to adenosine receptor activation might change during preeclamp-
sia; and how these phenomena might generate a compensatory
response via other adenosine receptors including A2BAR. As high-
lighted in this review, it is also necessary to determine whether
adenosine-mediated angiogenesis is present after birth in new-
borns and children exposed to preeclampsia. These studies are
difﬁcult to perform in humans due to ethical and technical issues;
but certainly animal models might help. Mice deﬁcient in each
one of the adenosine receptors have been developed, providing an
excellent model to address these last questions. We hope that this
review will contribute to awareness, within the scientiﬁc commu-
nity, of this important issue and stimulate further investigation in
this area.
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